AfterRaise/Companies/Tempo Therapeutics

Tempo Therapeutics

$14M UndisclosedRaised 2 days agoSan Diego, USABiotech & PharmaUSA
Visit website →

Why now

Where Tempo Therapeutics is today

Tempo Therapeutics announced a funding round of $14M on 18 September 2026, led by Interim CEO Eric Richman.

Latest round
Undisclosed
Amount
$14M
Announced
18 September 2026
Headquarters
San Diego, USA
Sector
Biotech & Pharma
Growth stage
Growth
Investors
Interim CEO Eric Richman
Also participating
Not stated
Relevant leadership
Not stated

Momentum AfterRaise intelligence

AfterRaise Score

62
Building momentum
1 funding signal in the last 90 days
Funding recency
40/40
announced within the last 30 days
Round scale
12/25
round size relative to the market
Funding stage
10/20
Undisclosed
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

In their own words

What Tempo Therapeutics says it is doing

Work here? Reserve your page

Public signal Described in the funding announcement as "regenerative medicine company". Source

Market expansionResearch and development

Public signal Read from the company's own description of what the funding supports.

Since the raise

What has happened since

  • 18 September 2026
    $14M raised
    Led by Interim CEO Eric Richman.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • New market entry
  • First local hires in the new market
  • Local entity and legal setup
  • Research programme expansion

Opportunities this could create

  • Clinical operations
  • Scientific hiring
  • Licensing and BD partnerships
  • Market-entry advisers
  • Local employment infrastructure

Based on the Biotech & Pharma sector, a Growth round and the priorities the company itself set out. Not a statement of fact.

Medium momentum3 connected signals
  • 18 September 2026$14M round announced
  • 18 September 2026Stated priority: market expansion
  • 18 September 2026Stated priority: research and development

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Tempo Therapeutics is open to

Not yet specified

Tempo Therapeutics has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Tempo Therapeutics

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Tempo Therapeutics?

Reserve your company page.

This page was created from publicly available information. When verified company accounts open, your team will be able to correct your profile, tell the market what you actually need and control how people approach you.

What we do not have yet: the roles and projects you have open and who leads the team. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every company administrator is verified before access is granted.

The first 1,000 verified funded companies join the Founding 1,000 free for life and keep Founding Company status permanently.

Also moving

Other Biotech & Pharma companies

See the sector